CSIMarket
 
Provectus Biopharmaceuticals Inc   (PVCT)
Other Ticker:  
 
 
Price: $0.2000 $-0.02 -7.792%
Day's High: $0.2245 Week Perf: -6.37 %
Day's Low: $ 0.20 30 Day Perf: 55.4 %
Volume (M): 689 52 Wk High: $ 0.22
Volume (M$): $ 138 52 Wk Avg: $0.12
Open: $0.22 52 Wk Low: $0.06



 Market Capitalization (Millions $) 84
 Shares Outstanding (Millions) 420
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc is a biotechnology company that focuses on developing innovative therapies for cancer and dermatological conditions. The company specializes in developing small molecule drugs and biologics that target specific molecular pathways involved in the progression of these diseases.

Provectus Biopharmaceuticals is best known for its drug candidate PV-10, which is being developed for the treatment of skin cancer, including metastatic melanoma. PV-10 is a selective small molecule drug that is injected directly into tumors, causing them to shrink or disappear. The drug has demonstrated promising results in clinical trials, showing high rates of complete response and minimal side effects.

In addition to its work on PV-10, Provectus Biopharmaceuticals is also involved in developing other drug candidates for various cancer types and dermatological conditions. The company utilizes its expertise in oncology, immunology, and molecular biology to develop novel therapies that have the potential to address unmet medical needs.

Overall, Provectus Biopharmaceuticals Inc is a biotechnology company that is dedicated to developing innovative therapies for cancer and dermatological conditions, with a particular focus on personalized medicine and targeted therapies.


   Company Address: 800 S. Gay Street Knoxville 37929 TN
   Company Phone Number: 594-5999   Stock Exchange / Ticker: PVCT
   PVCT is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Faces Severe Revenue Plunge and Net Shortfall in Q3 2023



Provectus Biopharmaceuticals Inc, a notable player in the healthcare industry, recently released its financial results for the fiscal period closing on September 30, 2023. However, the numbers painted a disappointing picture for the company, as it experienced a substantial decrease in revenue and a larger net shortfall compared to the previous year. Let's dive deeper into the details of these results and their potential implications for the stock market.
Revenue Plunge and Earnings:
During the fiscal period closing on September 30, 2023, Provectus Biopharmaceuticals Inc witnessed a severe decline in revenue. It plummeted by a staggering 77.855% compared to the same quarter a year ago, reaching a mere $0.07 million compared to $0.31 million. Moreover, when comparing the previous quarter, the revenue experienced a sharp sequential tumble of 56.913% from $0.16 million.

Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Faces Sharp Drop in Revenue, Reporting Zero Gain in the April to June 2023 Fiscal Interval

Financial News Report:
Provectus Biopharmaceuticals Inc Reports Zero Gain during April to June 2023 Fiscal Interval
During the fiscal interval of April to June 30, 2023, Provectus Biopharmaceuticals Inc reported zero gain of $0.00 per share, similar to the previous year. This figure also represents a decline from the preceding financial reporting period, where the gain was $0.00 per share.
Furthermore, the company experienced a significant decrease in revenue during the comparable financial reporting period a year ago. The revenue decreased by 49.693% to $0.16 million from $0.32 million. Sequentially, the revenue fell by 21.062% from $0.21 million.

Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Sets Earnings Record with $0.205025 Million in Q1 Revenue

Provectus Biopharmaceuticals reports $0.205025 million in revenue for Q1 of 2023
Provectus Biopharmaceuticals Inc, a leading pharmaceutical preparations company, has reported a revenue of $0.205025 million in the first quarter of 2023 earnings season. This is a significant increase over the similar quarter a year ago when the company reported a deficit of $-1.239 million.
The company has had a positive start to the financial year, with a net shortfall of $-0.827 million instead of a deficit in the first quarter. This impressive improvement is due to Provectus Biopharmaceuticals? commitment to innovation and technological advancements in the field of pharmaceuticals.






 

Provectus Biopharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com